Patents by Inventor Ji-Ming Wang

Ji-Ming Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A 2K CLEARCOAT COMPOSITION, ITS PREPARATION AND USE THEREOF
    Publication number: 20220372326
    Abstract: Described herein is a 2K clearcoat composition including, Component I including a). at least one resin having carboxylic acid groups with acid value of 50 to 400 mg KOH/g; b). at least one resin having hydroxyl functional groups with a hydroxyl value of 10 to 800 mg KOH/g; c). at least one catalyst; and d). at least one solvent, and Component II including e). at least one epoxy-functional alkoxysilane and/or its oligomer and/or its polymer; and f). at least one crosslinker reactive to hydroxyl groups. Also described herein are a substrate coated with the dried and cured 2K clearcoat composition and an automotive including the substrate.
    Type: Application
    Filed: June 22, 2020
    Publication date: November 24, 2022
    Inventors: Yang Zhang, Ji Ming Wang, Lei He, Christian Gerhard Schaefer, Wen Mei Liu, Ranjit Salvi, Stefan Hirsemann
  • T20/DP178 is an activator of human phagocyte formyl peptide receptors
    Patent number: 6830893
    Abstract: The present invention relates to the discovery that T20/DP178, T21/DP107, and fragments thereof interact with members of the formyl peptide receptor family and thereby modulate cell migration and activation. Novel biological tools, prophylactics, therapeutics and methods of use of the foregoing for modulating an inflammatory response are disclosed.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: December 14, 2004
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Ji Ming Wang, Joost J. Oppenheim, Shao-Bo Su, Wang Hua Gong, Ji-Liang Gao, Philip M. Murphy
  • Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
    Patent number: 6808877
    Abstract: The present invention relates to the discovery of molecules that inhibit viral infection and promote a host immune response to a pathogen. More specifically, the invention disclosed herein concerns molecules that interact with a FPR class receptor, inhibit HIV infection, and stimulate an inflammatory response in a subject. Embodiments of the invention include biotechnological tools, prophylactics, therapeutics, and methods of use of the foregoing, for the study, treatment, and prevention of HIV infection and the induction of an inflammatory response in a subject.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: October 26, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ji-Ming Wang, Yingying Le, WangHua Gong, Bao Qun Li, Thomas Rogers, Philip Murphy, Joost J. Oppenheim
  • T20/DP178 and T21/DP107 are activators of human phagocyte formyl peptide receptors
    Publication number: 20030203841
    Abstract: The present invention relates to the discovery that T20/DP178, T21/DP107, and fragments thereof interact with members of the formyl peptide receptor family and thereby modulate cell migration and activation. Novel biological tools, prophylactics, therapeutics and methods of use of the foregoing for modulating an inflammatory response are disclosed.
    Type: Application
    Filed: November 2, 2001
    Publication date: October 30, 2003
    Inventors: Ji Ming Wang, Joost J. Oppenheim, Shao-Bo Su, Wang-Hua Gong, Ji-Liang Gao, Philip Murphy
  • Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
    Publication number: 20030147883
    Abstract: The present invention relates to the discovery of molecules that inhibit viral infection and promote a host immune response to a pathogen. More specifically, the invention disclosed herein concerns molecules that interact with a FPR class receptor, inhibit HIV infection, and stimulate an inflammatory response in a subject. Embodiments of the invention include biotechnological tools, prophylactics, therapeutics, and methods of use of the foregoing, for the study, treatment, and prevention of HIV infection and the induction of an inflammatory response in a subject.
    Type: Application
    Filed: July 17, 2002
    Publication date: August 7, 2003
    Inventors: Ji-Ming Wang, Yingying Le, WangHua Gong, Bao Qun Li, Thomas Rogers, Philip Murphy, Joost J. Oppenheim
  • Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)
    Publication number: 20030120037
    Abstract: The present invention relates to the discovery that serum amyloid A (SAA) is a ligand for the FPRL1 receptor. Disclosed herein, are novel biological tools for the study of SAA/FPRL1 complex assembly and prophylactics, therapeutics, and methods of use of the foregoing, which modulate the association of SAA with FPRL1 and thereby effect responses including, but not limited to, signal transduction, chemotaxis, leukocyte migration, immune system response, amyloidosis, inflammatory response, infection, organ rejection, arthritis, atherosclerosis, and neoplasia.
    Type: Application
    Filed: March 14, 2002
    Publication date: June 26, 2003
    Inventors: Ji Ming Wang, Joost J. Oppenheim, Shao-Bo Su, Wang Hua Gong, Ji-Liang Gao, Philip M. Murphy
  • Chemotactic agents for t-cells
    Patent number: 5837247
    Abstract: Chemotactic activity of defensins and CAP37 is disclosed. Methods of treatment associated with such activity and compositions for such treatment are also provided.
    Type: Grant
    Filed: June 16, 1995
    Date of Patent: November 17, 1998
    Assignee: United States of America as represented by the Public Health Service National Institutes of Health
    Inventors: Joost J. Oppenhelm, Dennis Michiel, Oleg Chertov, Dennis D. Taub, Luoling Xu, Ji Ming Wang, William J. Murphy